Nirmatrelvir/ritonavir: real world drug-drug interaction management experience

被引：0

作者：

Bukhari, Shahid ^{[1
]}

Hughes, Stephen ^{[1
]}

Mughal, Nabeela ^{[1
]}

Moore, Luke S. P. ^{[1
,2
,3
]}

Davies, Gary ^{[1
]}

Zhang, Adrian Varghas ^{[2
]}

Ng, Megan ^{[2
]}

Karagozlu, Zekiye ^{[2
]}

Boffito, Marta ^{[1
,2
]}

机构：

[1] Chelsea & Westminster Hosp Fdn Trust, London, England

[2] Imperial Coll London, London, England

[3] Imperial Coll Healthcare NHS Trust, North West London Pathol, London, England

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2024年 / 22卷 / 09期

关键词：

Nirmatrelvir/ritonavir; drug-drug interactions; COVID-19; Paxlovid; real world;

D O I：

10.1080/14787210.2024.2389884

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

BackgroundIn the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.Research design and methodsWe analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.ResultsAmong 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.ConclusionsThis highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.

引用

页码：781 / 783

页数：3

共 50 条

[21] Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
Morganne Sindelar
Daniel McCabe
Elisabeth Carroll
Journal of Medical Toxicology, 2023, 19 : 45 - 48
[22] Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Marzolini, Catia
Kuritzkes, Daniel R.
Marra, Fiona
Boyle, Alison
Gibbons, Sara
Flexner, Charles
Pozniak, Anton
Boffito, Marta
Waters, Laura
Burger, David
Back, David J.
Khoo, Saye
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1191 - 1200
[23] Evaluation of Sources of Drug Interaction Information for Nirmatrelvir/ritonavir
Yoshikawa, Hiroshi
Tomita, Takashi
Shigita, Erika
Takamatsu, Hanae
Matsushima, Aoi
Yanagida, Tokue
Matsuo, Hiroaki
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2024, 144 (07): : 733 - 740
[24] Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir?
Fabbiani, Massimiliano
Navarra, Pierluigi
Cauda, Roberto
De Luca, Andrea
Di Giambenedetto, Simona
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (01) : E18 - E20
[25] Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
Lange, Nicholas W.
Salerno, David M.
Jennings, Douglas L.
Choe, Jason
Hedvat, Jessica
Kovac, Danielle
Scheffert, Jenna
Shertel, Tara
Ratner, Lloyd E.
Brown, Robert S., Jr.
Pereira, Marcus R.
AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (07) : 1925 - 1926
[26] A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions
Fu, Zhiqing
Guo, Yan
Li, Shuai
Shi, Yang
CARDIOLOGY DISCOVERY, 2025, 5 (01): : 91 - 93
[27] Nirmatrelvir+ritonavir/tacrolimusIncreased tacrolimus concentration following drug-drug interaction leading to various toxicities: case report
Reactions Weekly, 2023, 1978 (1) : 291 - 291
[28] A CASE OF CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTIONS OF PAXLOVID (NIRMATRELVIR/RITONAVIR) WITH CONCURRENT MEDICATIONS IN THE MANAGEMENT OF COVID-19
Weill, Sydney
Reddy, Anisha
Bugos, Eva
JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S370 - S370
[29] Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients
Cordero, Carlos Guzman
de Vicente, Maria Saez-Torres
Espinosa, Alvaro Jimenez
Sanchez, Ana Isabel Gago
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
[30] Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID®) with Concomitant Medications in Real-World Clinical Settings
Zatovkanukova, Petra
Vesely, Dalibor
Sliva, Jiri
PATHOGENS, 2024, 13 (12):

← 1 2 3 4 5 →